idiopathic thrombocytopenic purpura


Also found in: Dictionary, Thesaurus, Medical, Acronyms, Wikipedia.

idiopathic thrombocytopenic purpura

[¦id·ē·ə¦path·ik ¦thräm·bō‚sīd·ə′pē·nik ′pər·pyə·rə]
(medicine)
Thrombocytopenic purpura of unknown causes.
References in periodicals archive ?
Helicobacter pilory eradication can induce platelet recovery in idiopathic thrombocytopenic purpura. Blood 2001; 97:812-814.
Kurata et al., "Is eradication therapy useful as the first line of treatment in Helicobacter pylori-positive idiopathic thrombocytopenic purpura? Analysis of 207 eradicated chronic ITP cases in Japan," International Journal of Hematology, vol.
Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study.
Idiopathic Thrombocytopenic Purpura or Immune Thrombocytopenia (ITP) as new guidelines suggest is an acquired autoimmune disease characterised by platelet destruction caused by anti-platelet auto antibodies.1
Reliable predictors of neonatal immune thrombocytopenia in pregnant women with idiopathic thrombocytopenic purpura. Am J Hematol.
It was followed by hereditary spherocytosis with 29.4% (5/17) and refractory Idiopathic Thrombocytopenic Purpura having 11% (2/17) of the cases.
Idiopathic thrombocytopenic purpura (ITP) is an acquired autoimmune disorder characterized by thrombocytopenia and mucocutaneous bleeding and it may occur acutely, chronically or recurrently.
Platelet-associated autoantibodies as detected by a solid-phase modified antigen capture ELISA test (MACE) are a useful prognostic factor in idiopathic thrombocytopenic purpura. Blood 2004; 103: 4562-4.
Idiopathic thrombocytopenic purpura complicating pregnancy.
It was launched for the treatment of idiopathic thrombocytopenic purpura (ITP) and has contributed to many ITP patients since April 2011.
Piper Jaffray analyst Danielle Brill maintained an Overweight rating and $35 price target on Momenta following the company's Q1 results, saying Momenta continued to advance its pipeline in the quarter, initiating Phase 2 trials with M281, its anti-FcRn candidate, in hemolytic disease of the fetus and newborn and myasthenia gravis, as well as a Phase 1/2 proof-of-concept trial of M254, a hyper-sialyated IVIG, for idiopathic thrombocytopenic purpura, adding that all trials are reportedly progressing as planned.

Full browser ?